Allergan, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 108   

Articles published

AGN 240.22
price chart
Sale of Allergan to Actavis is finalized; CEO David Pyott stepping down
Actavis won a bidding war to acquire Allergan, which spent about six months fighting a takeover bid by Canadian company Valeant Pharmaceuticals International Inc. and its partner, activist investor Bill Ackman. Allergan had opposed Valeant's offer in ...
Actavis Completes Acquisition of Allergan  Wall Street Journal
European Commission Clears Actavis' Pending Acquisition of Allergan  MarketWatch
Talking Allergan at Tulane: a 'Horse Choker,' the 'Shamarendum' and More
The deal, Allergan Inc.'s $66 billion sale to Actavis PLC, closed just two days earlier, ahead of schedule and 11 months after Valeant Pharmaceuticals International Inc. and activist William Ackman's hedge-fund firm had first gone public with an ...
Pershing Square Holdings: First Annual Report (registration)
Actavis Plc, Allergan, Inc. (AGN) Shareholders Vote In Favor Of $66 Billion Merger
Actavis plc (NYSE:ACT), an integrated specialty pharmaceutical company, and Botox-maker Allergan, Inc. (NYSE:AGN) announced on Tuesday that the shareholders of the two companies had okayed the $66 billion merger and all the proposals related to the ...
Analytic Report on Allergan Inc. (NYSE:AGN)  Markets Wired
Actavis, Allergan Shareholders Approve $66 Billion Deal  Wall Street Journal
Douglas Ingram of Allergan, Inc. Elected to the Board of Pacific Mutual ...
Irvine-based Allergan, Inc. is a multi-specialty health care company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products.
The Acquisition Deal between Actavis Plc (NYSE:ACT) and Allergan Inc. (NYSE ...
Actavis plc (NYSE:ACT) successfully managed to acquire Allergan Inc. (NYSE:AGN) and approximately a deal of $71 billion was delineated.
Actavis plc. (NYSE:ACT) Shares plunged as Goldman Sachs place the stock on ...  Inside Trade
Allergan, Inc. Short Interest Disclosure
Allergan, Inc. (NYSE:AGN) encountered a rise of 7% or 168,741 shares in the short positions. The number escalated from 2,404,544 on February 13,2015 to 2,573,285 on February 27,2015.
First Call Rating Update on Allergan, Inc.
Allergan, Inc. (NYSE:AGN) has been rated as Buy in the consensus recommendation of First Call Corporation, a division of Thomson Reuters.
Investors Sell Allergan on Strength (AGN)  Intercooler
American Airlines Replaces Allergan in S&P 500
American Airlines Group Inc. (NASDAQ: AAL) will be the newest addition to the S&P 500, taking the place of Allergan Inc. (NYSE: AGN). The change will occur after the close of trading Friday, March 20, and it will have a couple implications for the ...
S&P 500: American Airlines replaces Allergan
American Airlines Group To Replace Allergan In S&P 500  RTT News
Allergan Cost Synergies On Track For Large Upside
AGN is positioned well to take advantage of attractive industry growth; we believe management is conservative about its estimates on revenue projections.
Investors Sell Shares of Allergan on Strength (AGN)  WKRB News
Hot Healthcare Stocks - Allergan (AGN), Organovo (ONVO), Anacor (ANAC ...  Techsonian (press release)
Allergan Inc. (AGN) is Trading Higher on Unusual Volume for March 12
Allergan Inc. ($AGN) experienced unusually high volume on Mar. 12, as the stock gained 0.81% to a closing price of $237.17.